Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like What Biogen CFO's Departure Means for Company's M&A Strategy June 14, 2017 Backed by Amazon and Big Names Like Bristol-Myers Squibb, Celgene and Merck & Co., Bay Area's GRAIL Banks $900 Million March 1, 2017 FDA Release: Mutual Recognition Promises New Framework For Pharmaceutical Inspections For United States And European Union March 1, 2017
Backed by Amazon and Big Names Like Bristol-Myers Squibb, Celgene and Merck & Co., Bay Area's GRAIL Banks $900 Million March 1, 2017
FDA Release: Mutual Recognition Promises New Framework For Pharmaceutical Inspections For United States And European Union March 1, 2017
